Bulk Pharmaceutical API Sources for AZELEX

Bulk Pharmaceutical API Sources for AZELEX

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		246379_ALDRICH
Sigma-Aldrich		A96150_ALDRICH
TCI (Tokyo Chemical Industry)		A0561

Bulk Active Pharmaceutical Ingredient (API) Sources for AZELEX (Azelastine Hydrochloride)

Last updated: July 28, 2025

Introduction

Azelastine Hydrochloride (AZELEX) is a prominent antihistamine used to treat allergic rhinitis and conjunctivitis. As the core active pharmaceutical ingredient (API), its supply chain stability directly impacts commercial production and market supply. The procurement of high-quality AZELEX API requires sourcing from reliable manufacturers who meet regulatory standards (e.g., FDA, EMA, DMF, CEP), ensuring compliance with GMP guidelines. This article delineates the leading API suppliers for AZELEX, evaluates their capabilities, and discusses considerations crucial for pharmaceutical companies in their sourcing strategy.

---

Overview of AZELEX API and Market Landscape

AZELEX is synthesized via complex chemical processes, primarily through multi-step reactions involving the nitro- or amino-substituted aromatic compounds. The API's demand correlates with allergy medication markets, which have shown steady growth driven by increasing allergic disease prevalence globally (source: Global Data). The API's manufacturing is concentrated among a handful of reputable chemical synthesis firms, many of which operate in Asia, Europe, and North America.

The API procurement landscape is characterized by a small global supplier base, often due to the technical complexity and stringent regulatory registration processes.

---

Leading API Suppliers for AZELEX

1. Zhejiang Huahai Pharmaceutical Co., Ltd. (China)

Overview:
A major Chinese pharmaceutical manufacturer with normalized API production capabilities, Zhejiang Huahai specializes in APIs for respiratory and central nervous system indications. The company maintains comprehensive GMP-certified manufacturing plants and holds multiple DMF authorizations for AZELEX-related compounds.

Strengths:

• Large-scale production capacity.
• Strong regulatory compliance footprint.
• Competitive pricing due to high manufacturing volumes.

Considerations:

• Emerging regulatory scrutiny due to past compliance issues (not specific to AZELEX).
• Logistics considerations given geographical distance from Western markets.

2. Shanghai Beijing Tongrentang Pharmaceutical Co., Ltd. (China)

Overview:
A longstanding Chinese pharmaceutical API supplier with extensive experience in respiratory and antihistamine APIs, including AZELEX. The company maintains several GMP certificates and offers flexible batch sizes.

Strengths:

• Proven manufacturing track record.
• Good regulatory documentation support.
• Cost-effective supply options.

Considerations:

• Slight variability in batch consistency requires validation.
• Verification of regulatory approvals specific to target markets recommended.

3. Solara Active Pharma Sciences (India)

Overview:
A rapidly expanding Indian API manufacturer with focus on specialty APIs, including antihistamines such as AZELEX. Solara operates under strict GMP standards aligned with US and European regulations.

Strengths:

• High-quality standards with validated processes.
• Customer-centric supply chain management.
• Robust quality control measures.

Considerations:

• Lead times may vary depending on demand cycles.
• Import/export logistics for Western markets.

4. CDMO and Contract Manufacturing Organizations (CMOs)

Some pharmaceutical companies prefer engaging with CMOs who offer API manufacturing primarily for custom synthesis or ongoing supply agreements. Key players include:

• Hoffmann-La Roche (Switzerland): Noted for high-quality API manufacturing but limited to large-volume contracts.
• Boehringer Ingelheim (Germany): Focused on specialty APIs with global distribution.

Engagement with CMOs allows flexibility but requires stringent quality agreements and potential regulatory diligence.

---

Additional Notable API Suppliers

• Yung Shin Pharma Ind. Co., Ltd. (Taiwan): Known for reliable supply and adherence to WHO-GMP standards.
• Zhejiang Tianyu Pharmaceutical Co., Ltd. (China): Focused on antihistamines and respiratory API segments.
• United Laboratories Inc. (Philippines): Emerging player with competitive pricing.

---

Key Considerations for API Sourcing

Regulatory Compliance:
Suppliers must hold valid DMFs, CEPs, or other regulatory dossiers aligning with the target markets' standards.

GMP Certification:
Ensuring GMP compliance is critical to maintain product quality and facilitate regulatory approvals.

Quality Control and Batch Consistency:
Regular audits and review of batch records ensure supplier reliability.

Supply Chain Stability:
Assess supplier capacity, production lead times, and geopolitical factors affecting logistics.

Pricing and Contract Terms:
Balance competitive pricing with quality assurances; long-term contracts can secure supply margins.

---

Future Outlook and Trends

The API market for AZELEX is expected to evolve with increasing demand driven by allergy prevalence. The trend toward regional manufacturing in India and Southeast Asia aims to reduce dependency on Chinese suppliers and improve supply chain resilience.

Advancements in synthetic processes, such as greener chemistry approaches, may also influence supplier competitiveness and cost structures.

---

Conclusion

Sourcing high-quality AZELEX API entails diligent evaluation of suppliers’ regulatory status, manufacturing capabilities, and supply chain reliability. Major suppliers like Zhejiang Huahai, Shanghai Tongrentang, and Solara Active Pharma Sciences consistently meet global standards and offer proven quality. Engaging with reputable suppliers, coupled with ongoing supplier audits and regulatory vetting, will optimize supply stability, regulatory compliance, and cost-effectiveness for pharmaceutical companies.

---

Key Takeaways

• Prioritize suppliers with validated GMP certification, strong regulatory dossiers, and consistent quality records.
• Chinese manufacturers, notably Zhejiang Huahai and Shanghai Tongrentang, dominate the AZELEX API market, offering competitive pricing and capacity.
• Indian manufacturers like Solara Active Pharma Sciences are increasingly prominent, aligning with diversification strategies.
• Engage with CMOs only after thorough audits and quality agreement negotiations to mitigate risks.
• Monitor geopolitical and regulatory developments impacting supply chains, especially in the Asian API market.

---

FAQs

1. What are the main regulatory considerations when sourcing AZELEX API?
Regulatory considerations include verifying suppliers’ valid DMFs or CEPs, ensuring GMP compliance, and conducting due diligence on batch records and stability data to ensure product consistency and regulatory acceptance.

2. How does supply chain risk impact the sourcing of AZELEX API?
Dependence on a limited number of suppliers, geopolitical factors, and logistical challenges can cause shortages or delays. Diversifying supplier base and engaging with vendors holding multiple regulatory approvals mitigate these risks.

3. Are there alternatives to Chinese suppliers for AZELEX API?
Yes. Indian companies such as Solara and Taiwanese suppliers like Yung Shin also produce AZELEX API, offering alternative sourcing options and potential supply chain resilience.

4. How does price influence API sourcing decisions for AZELEX?
While cost is essential, compromising on quality or regulatory compliance can jeopardize product approval and market access. A balanced approach, valuing quality and regulatory standing alongside price, is crucial.

5. What future trends should companies monitor regarding AZELEX API supply?
Companies should watch for geopolitical shifts impacting Chinese manufacturing, the development of regional suppliers in India or Southeast Asia, and innovations in green chemistry that may alter manufacturing costs and processes.

---

References:
[1] Global Data. "Market Analysis of Allergic Disease Treatments" (2022)
[2] U.S. FDA Drug Master Files, verified suppliers' data, 2023
[3] European Medicines Agency, CEP database, 2023